The two-part test for grant of supplementary protection certificates is here to stay, but at what price?

ADVERTISING MEDICINAL PRODUCTS IN THE INTERIM PERIOD BETWEEN MARKETING AUTHORISATION AND THE DECISION ON PRICING AND PUBLIC FUNDING

16 November 2021 No Comments

This paper analyses the promotion of medicines for human use that have already received marketing authorization, when the advertising is made before the resolution on pricing and inclusion in the Spanish National Health Service. This is an issue addressed by

Promotion of Research through IP protection

28 October 2021 No Comments

Three of the most recognized experts on IP farma in Spain Ángel García Vidal, profesor de Derecho Mercantil de la Universidad de Santiago de Compostela y Consejero Académico de Gómez Acebo y Pombo, Kiko Carrión García de Parada, Abogado socio

DEBATE ON ADVANCED THERAPIES AND BIOLOGICAL MEDICINAL PRODUCTS

28 October 2021 No Comments

Jorge Muñoz, Member of CEFI Board lead the debate on advanced therapies an biological medicinal products. Sol Ruíz, Jefe de División de Productos Biológicos, Terapias Avanzadas y Biotecnología de la Agencia Española de Medicamentos y Productos Sanitarios and Jordi Faus,

Clinical Research and data protection debate

27 October 2021 No Comments

Interesting debate with Jesús Rubí, Adjunto a la Dirección de la Agencia Española de Protección de Datos, Amelia Martín Uranga, Responsable de la Plataforma de Medicamentos Innovadores de Farmaindustria and Lluis Alcover, Abogado de Faus y Moliner. Interestingf debate about main

STRONG INTEREST IN OUR DISCUSSION ON OBSERVATIONAL STUDIES ON MEDICATIONS AND PATIENT SUPPORT PROGRAMMES

27 October 2021 No Comments

On 15 October we had an interesting discussion on Observational Studies on Medications and patient support programmes in the new regulations that aroused a lot of interest. More than 90 people participated in the session with strong participation in questions

Advertising of medicinal products before a financing decision by the National Health System

27 October 2021 No Comments

Superior Court of Justice of the Basque Country, Judicial Review Chamber, Judgment 246/2021 of 30 June resolved positively on a question widely debated in the sector: the possibility of advertising medicinal products that have been approved for sale but have

The two-part test for grant of supplementary protection certificates is here to stay, but at what price?

Otras noticias

ADVERTISING MEDICINAL PRODUCTS IN THE INTERIM PERIOD BETWEEN MARKETING AUTHORISATION AND THE DECISION ON PRICING AND PUBLIC FUNDING

Promotion of Research through IP protection

DEBATE ON ADVANCED THERAPIES AND BIOLOGICAL MEDICINAL PRODUCTS

Clinical Research and data protection debate

STRONG INTEREST IN OUR DISCUSSION ON OBSERVATIONAL STUDIES ON MEDICATIONS AND PATIENT SUPPORT PROGRAMMES

Advertising of medicinal products before a financing decision by the National Health System

Address

Information

Contact